과제정보
연구 과제 주관 기관 : Ministry of Food and Drug Safety
참고문헌
- Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119-137. https://doi.org/10.1146/annurev.med.56.082103.104724
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205. https://doi.org/10.1001/jama.279.15.1200
- Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123-129. https://doi.org/10.1016/j.tox.2004.12.022
- Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg 1996;15:236-243. https://doi.org/10.1016/S1085-5629(96)80036-8
- Strom BL, Carson JL, Halpern AC, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991;127:831-838. https://doi.org/10.1001/archderm.1991.01680050075007
- Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-813. https://doi.org/10.1586/eci.11.66
- Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39. https://doi.org/10.1186/1750-1172-5-39
- Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006;55:27-33. https://doi.org/10.2332/allergolint.55.27
- Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123:1171-1173. https://doi.org/10.1001/archderm.1987.01660330082014
- Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007;7:317-323. https://doi.org/10.1097/ACI.0b013e3282370c5f
- Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011;128:1266-1276. https://doi.org/10.1016/j.jaci.2011.08.013
- Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579. https://doi.org/10.1056/NEJMoa0706135
- Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-1122. https://doi.org/10.1016/S0140-6736(02)08158-8
- Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-732. https://doi.org/10.1016/S0140-6736(02)07873-X
- Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-211. https://doi.org/10.1517/phgs.5.2.203.27481
- Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-1118. https://doi.org/10.1086/529382
- Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005;65:437-447. https://doi.org/10.1111/j.1399-0039.2005.00386.x
- Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: a multicentre retrospective cohort study. Eur Radiol 2017;27:2886-2893. https://doi.org/10.1007/s00330-016-4682-y
- Park WB, Choe PG, Song KH, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009;48:365-367. https://doi.org/10.1086/595890
- Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008;9:207-214. https://doi.org/10.2217/14622416.9.2.207
- Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011;127(3 Suppl):S60-S66. https://doi.org/10.1016/j.jaci.2010.11.046
- Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009;19:139-146. https://doi.org/10.1097/FPC.0b013e32831d0faf
- Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-99. https://doi.org/10.1097/00002030-200501030-00014
- Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21:264-265. https://doi.org/10.1097/QAD.0b013e32801199d9
- Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486. https://doi.org/10.1038/428486a
- Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011;364:1126-1133. https://doi.org/10.1056/NEJMoa1009717
- Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012;79:1259-1267. https://doi.org/10.1212/WNL.0b013e31826aac73
- Kuehn BM. FDA: epilepsy drugs may carry skin risks for Asians. JAMA 2008;300:2845. https://doi.org/10.1001/jama.2008.890
- Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-1546. https://doi.org/10.2217/14622416.9.10.1543
- Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 2006;6:265-268. https://doi.org/10.1038/sj.tpj.6500356
- Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-1622. https://doi.org/10.2217/14622416.9.11.1617
- Devi K. The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. Int J Dermatol 2018;57:70-73. https://doi.org/10.1111/ijd.13812
- Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-1018. https://doi.org/10.1111/j.1528-1167.2007.01022.x
- Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010;51:926-930. https://doi.org/10.1111/j.1528-1167.2010.02533.x
- Then SM, Rani ZZ, Raymond AA, Ratnaningrum S, Jamal R. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011;29:290-293.
- Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012;92:757-765. https://doi.org/10.1038/clpt.2012.189
- Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011;20:1034-1041. https://doi.org/10.1093/hmg/ddq537
- McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-1143. https://doi.org/10.1056/NEJMoa1013297
- Khor AH, Lim KS, Tan CT, et al. HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. Pharmacogenet Genomics 2017;27:275-278. https://doi.org/10.1097/FPC.0000000000000287
- Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-197. https://doi.org/10.1016/j.eplepsyres.2011.08.010
- Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-356. https://doi.org/10.2217/pgs.09.162
- Ramirez E, Bellon T, Tong HY, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)- induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res 2017;115:168-178. https://doi.org/10.1016/j.phrs.2016.11.027
- Kazeem GR, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009;19:661-665. https://doi.org/10.1097/FPC.0b013e32832c347d
- Kim BK, Jung JW, Kim TB, et al. HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population. Ann Allergy Asthma Immunol 2017;118:629-630. https://doi.org/10.1016/j.anai.2017.02.011
- Koomdee N, Pratoomwun J, Jantararoungtong T, et al. Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population. Front Pharmacol 2017;8:879. https://doi.org/10.3389/fphar.2017.00879
- Moon J, Park HK, Chu K, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia 2015;56:e161-e167. https://doi.org/10.1111/epi.13087
- Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139. https://doi.org/10.1073/pnas.0409500102
- Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-709. https://doi.org/10.1097/FPC.0b013e328330a3b8
- Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-307. https://doi.org/10.1097/FPC.0b013e32834282b8
- Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107. https://doi.org/10.1097/FPC.0b013e3282f3ef9c
- Goncalo M, Coutinho I, Teixeira V, et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 2013;169:660-665. https://doi.org/10.1111/bjd.12389
- Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011;26:3567-3572. https://doi.org/10.1093/ndt/gfr060
- Jung JW, Kim DK, Park HW, et al. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. Genet Med 2015;17:807-814. https://doi.org/10.1038/gim.2014.195
- Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 2015;351:h4848.
- Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol 1997;115:550-553. https://doi.org/10.1001/archopht.1997.01100150552021
- Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010;11:879-884. https://doi.org/10.2217/pgs.10.54
- Jee YK, Kim S, Lee JM, Park HS, Kim SH. CD8(+) T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Allergy 2017;47:972-974. https://doi.org/10.1111/cea.12919
- Yang F, Xuan J, Chen J, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J 2016;16:83-87. https://doi.org/10.1038/tpj.2015.25
- Jiang YY, Nguyen GH, Jin HZ, Zeng YP. Methazolamide-induced toxic epidermal necrolysis in a man carrying HLA-B*59:01: successful treatment with infliximab and glucocorticoid. Int J Dermatol 2018;57:494-496. https://doi.org/10.1111/ijd.13924
- Shu C, Shu D, Tie D, et al. Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01. Int J Dermatol 2015;54:1242-1245. https://doi.org/10.1111/ijd.12651
- Her Y, Kil MS, Park JH, Kim CW, Kim SS. Stevens-Johnson syndrome induced by acetazolamide. J Dermatol 2011;38:272-275. https://doi.org/10.1111/j.1346-8138.2010.00921.x
- Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012;92:194-199. https://doi.org/10.2340/00015555-1268
- Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013;369:1620-1628. https://doi.org/10.1056/NEJMoa1213096
- Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014;96:542-548. https://doi.org/10.1038/clpt.2014.159
- Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol 2013;69:1909-1916. https://doi.org/10.1007/s00228-013-1549-x
피인용 문헌
- Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea vol.60, pp.2, 2018, https://doi.org/10.3349/ymj.2019.60.2.208
- Personalisierte Medizin in der Allergologie vol.70, pp.1, 2018, https://doi.org/10.1007/s00105-018-4320-5
- The role of pharmacogenomics in adverse drug reactions vol.12, pp.5, 2019, https://doi.org/10.1080/17512433.2019.1597706
- Adverse drug reactions vol.62, pp.9, 2018, https://doi.org/10.5124/jkma.2019.62.9.472
- Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations vol.12, pp.11, 2018, https://doi.org/10.3390/pharmaceutics12111021
- Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in South Korea vol.8, pp.None, 2021, https://doi.org/10.3389/fmed.2021.640360
- Diagnosis and Management of Antibiotic Allergies vol.96, pp.4, 2018, https://doi.org/10.3904/kjm.2021.96.4.328
- Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art vol.17, pp.9, 2021, https://doi.org/10.1080/17425255.2021.1946514
- A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine vol.14, pp.11, 2018, https://doi.org/10.3390/ph14111077
- Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions vol.22, pp.24, 2021, https://doi.org/10.3390/ijms222413302